Melbourne, FL -- July 25, 2023 -- InvestorsHub NewsWire
--
Branded Legacy, Inc. (OTC.PK:
BLEG), a holding company specializing in growth through
acquisitions with a focus on the biotech industry, announced today
…
We have conducted an investor teleconference to announce our
significant strategic transformation and bold expansion plans
within the biotechnology sector. Led by Chief Executive Officer and
Chairman, David Oswald, the company outlined its achievements over
the past year and the vision for its future prospects.
During the teleconference, Mr. Oswald detailed the company's
successful restructuring efforts, which involved spinning off
subsidiaries like Spikes CBDX and Elev8 Hemp, as well as releasing
Delta Growers and Versatile Industries LLC. The focus on maximizing
long-term value by carrying only assets aligned with the company's
mission was emphasized.
Mr. Oswald introduced key members of the executive leadership team,
including Chief Technical Officer Brandon Arndt, Chief Research
Officer Jesse Morris, Chief Marketing Officer Doug Holladay, and
Chief Operating Officer Joe Holladay. The team possesses extensive
expertise in various fields, such as pharmaceutical biotechnology,
mycology, web development, and marketing.
Strategic Plans:
Royal Biotek unveiled a six-month plan to secure its desired market
share and create value for stakeholders. The company is in the
process of acquiring subsidiaries, including Rocket Web Development
and Design and MycoEnlighten, to enhance its capabilities in web
development and mycology. A state-of-the-art lab facility is being
established, enabling the processing of raw materials and compounds
with high efficiency.
Additionally, the company aims to establish revenue streams through
co-packing services and corporate partnerships, expanding its reach
and customer base. To reflect its new focus in the biotechnology
industry, the company will undergo a name change from Branded
Legacy to Royal Biotek, with a new stock symbol, RTEK.
Long-term Growth:
Mr. Oswald stressed the company's commitment to long-term growth
through targeted acquisitions, diversification of product
offerings, and sustainability initiatives. Royal Biotek aims to
research stable alkaloids, improve delivery systems, and conduct
clinical trials to gain FDA approval for its pharmaceutical
products. The company also plans to explore genetic consulting for
industrial crop varieties to produce alkaloids and other materials
simultaneously.
Mr. Oswald expressed confidence in the team's ability to
consistently produce high-purity end products, which will further
strengthen Royal Biotek's position in the biotechnology
sector.
"This will give us the opportunity to command portions of a much
larger market than would otherwise have been available, as we will
be able to more directly market these products for their intended
uses" says Oswald during the conference.
Branded Legacy's investor teleconference marked a pivotal moment in
the company's transformation and expansion into the biotechnology
sector. With its innovative therapies and strategic acquisitions,
the company is poised to revolutionize the healthcare industry and
deliver cutting-edge solutions to patients worldwide.
For further information and updates on Branded Legacy's progress,
please visit their website at brandedlegacy.com or contact the
company at info@BrandedLegacy.com.
A Recording the of conference can be downloaded or listened to
here:
https://brandedlegacy.com/wp-content/uploads/Teleconference-20230724-Branded-Legacy.mp3
About Branded Legacy (Royal Biotek):
Branded Legacy (OTC.PK:
BLEG), is a biotechnology company dedicated to advancing
scientific innovation and improving patient care through
plant-derived medicines. With a focus on maximizing long-term
value, the company is committed to developing novel therapies and
exploring the potential of functional mushrooms and other botanical
compounds.
Media Contact:
Philip White
Chief Compliance Officer
Branded Legacy
Phone: (407) 337-0642
Email: info@brandedlegacy.com
Safe Harbor Statement: The
information posted in this release may contain forward-looking
statements within the meaning of the Private Securities
Litigation Reform Act of 1995. You can identify these
statements by the use of the words "may," "will," "should,"
"plans," "expects," "anticipates," "continue,"
"estimate," "project," "intend," and similar expressions.
Forward-looking statements involve risks and uncertainties that
could cause actual results to differ materially from
those projected or anticipated. These risks and uncertainties
include, but are not limited to, general economic and
business conditions, effects of continued geopolitical unrest and
regional conflicts, competition, changes in
technology and methods of marketing, delays in
completing various engineering and manufacturing programs, changes
in customer order patterns, changes in product mix,
continued success in technological advances and delivering
technological innovations, shortages in
components, production delays due to performance
quality issues with outsourced components, and various other
factors beyond the Company's control.
Branded Legacy (PK) (USOTC:BLEG)
Historical Stock Chart
From Apr 2024 to May 2024
Branded Legacy (PK) (USOTC:BLEG)
Historical Stock Chart
From May 2023 to May 2024
